MEDISIEVE PAVES WAY FOR GROWTH AND PRODUCT DEVELOPMENT WITH GRANTS FROM INNOVATE UK 

Expands team to meet goals around developing Sepsis product 

After receiving two grants worth a total of £1.56m, MediSieve announces that the company has doubled in size since the start of the year, with the recruitment of three biochemists, a regulatory analyst and an immunologist, as well as expanding their office and laboratory space.

MediSieve, a medical device organisation developing "magnetic blood filtration": a ground-breaking treatment for blood-borne diseases which filters pathogens directly from the bloodstream, has just been awarded the two grants from Innovate UK.

Joining the MediSieve team as associate biochemists are Ana Skelton-Garcia, Manishankar Chellappan and Silvia Prelez, while Dr Kerstin Stegmann joins the technical management team as an immunologist. They will work together to help develop, test and validate MediSieve’s magnetic particle products for Sepsis.

Jonathan Kelly, quality and regulatory analyst, will assist in drafting the company’s regulatory documentation, managing technical files and establishing an ISO 13485 compliant Quality Management System.

“The grants from Innovate UK are of huge benefit to us. Firstly, they will enable us to accelerate our development and validation of more varied products to address the various challenges which Sepsis presents and secondly, it has allowed us to double our team and expand our office space and laboratory capacity.” said George Frodsham, MediSieve’s founder and CEO.
 

Worth a total of around £1.56m the grants include one large biomedical catalyst grant to progress development of a severe Sepsis product, developing five magnetic particles to remove different Sepsis targets.

The second SRBI grant enables further focus on one of those particles and how it can be used to remove anti-microbial resistant (AMR) bacteria from a patient’s bloodstream.

Both grants are two-year projects, starting in 2019, and involve distinct experimental pathways which can be delivered simultaneously with the added benefit that areas of synergy and overlap reduce workload.

Sepsis is a life-threatening infection that causes the body to attack its own organs and tissues. It kills 44,000 individuals in the UK and affects 20 million people globally each year. Six million of these are babies and children.

The horrifying figures around deaths from Sepsis illustrate just how important it is for MediSieve to develop its products and bring them to market, and therefore patients, just as soon as it can.

The company’s goals are to conduct the first in-lab validation during 2019 and then conduct animal studies during 2019/2020 followed by clinical trials in 2020/2021.

“We are continuously applying for grants and it is extremely gratifying when they are awarded to us, delivering recognition of the product development work we are conducting,” said Frodsham.

“This is a really exciting time for MediSieve and it’s great to welcome our new recruits who will join us at our base within the Translation & Innovation Hub (I-HUB), part of the Imperial College Incubator for science companies, where we moved in late 2017.”

The I-HUB is designed as an innovation and collaboration hub for growing technology startups and established biotech businesses.

“I am sure our new team members will flourish in the collaborative environment of the

I-HUB and help to ensure that MediSieve achieves its goals around developing products that can beat Sepsis,” said Frodsham.
 

About MediSieve

MediSieve is a medical device organisation developing "magnetic blood filtration": a ground-breaking treatment for blood-borne diseases which filters pathogens directly from the bloodstream.

For more information, visit www.medisieve.com

To find our more, contact pr@redheadpr.co.uk